Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM.

Am J Nephrol. 2013;37(3):212-22. doi: 10.1159/000346948. Epub 2013 Feb 28.

PMID:
23467003
[PubMed - indexed for MEDLINE]
2.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators.

N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.

PMID:
24206459
[PubMed - indexed for MEDLINE]
Free Article
3.

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG; BEAM Study Investigators.

N Engl J Med. 2011 Jul 28;365(4):327-36. doi: 10.1056/NEJMoa1105351. Epub 2011 Jun 24.

PMID:
21699484
[PubMed - indexed for MEDLINE]
Free Article
4.

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.

Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D.

Nephrol Dial Transplant. 2013 Nov;28(11):2841-50. doi: 10.1093/ndt/gft445.

PMID:
24169612
[PubMed - in process]
5.

Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis.

Warnock DG, Hebbar S, Bargman J, Burkart J, Davies S, Finkelstein FO, Mehrotra R, Ronco C, Teitelbaum I, Urakpo K, Chertow GM.

Contrib Nephrol. 2012;178:157-63. doi: 10.1159/000337837. Epub 2012 May 25. Review.

PMID:
22652731
[PubMed - indexed for MEDLINE]
6.

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.

Ruiz S, Pergola PE, Zager RA, Vaziri ND.

Kidney Int. 2013 Jun;83(6):1029-41. doi: 10.1038/ki.2012.439. Epub 2013 Jan 16. Review.

PMID:
23325084
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

PMID:
19145003
[PubMed - indexed for MEDLINE]
Free Article
8.

The extinguished BEACON of bardoxolone: not a Monday morning quarterback story.

Tayek JA, Kalantar-Zadeh K.

Am J Nephrol. 2013;37(3):208-11. doi: 10.1159/000346950. Epub 2013 Feb 28. No abstract available. Erratum in: Am J Nephrol. 2013;37(5):507.

PMID:
23466901
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.

Himmelfarb J, Tuttle KR.

N Engl J Med. 2014 May 1;370(18):1768-9. No abstract available.

PMID:
24804308
[PubMed - indexed for MEDLINE]
10.

Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.

Ellison DH.

N Engl J Med. 2014 May 1;370(18):1768. doi: 10.1056/NEJMc1400872#SA3. No abstract available.

PMID:
24785223
[PubMed - indexed for MEDLINE]
11.

Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.

Molnár GA, Kovács T, Wittmann I.

N Engl J Med. 2014 May 1;370(18):1767-8. doi: 10.1056/NEJMc1400872#SA2. No abstract available.

PMID:
24785222
[PubMed - indexed for MEDLINE]
12.

Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.

Chartoumpekis DV, Sykiotis GP.

N Engl J Med. 2014 May 1;370(18):1767. doi: 10.1056/NEJMc1400872#SA1. No abstract available.

PMID:
24785221
[PubMed - indexed for MEDLINE]
13.

Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.

Chertow GM, de Zeeuw D; BEACON Steering Committee.

N Engl J Med. 2014 May 1;370(18):1768. doi: 10.1056/NEJMc1400872. No abstract available.

PMID:
24785220
[PubMed - indexed for MEDLINE]
Free Article
14.

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators.

Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8. doi: 10.2215/CJN.03350708. Epub 2008 Dec 31.

PMID:
19118120
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Efficient and scalable synthesis of bardoxolone methyl (cddo-methyl ester).

Fu L, Gribble GW.

Org Lett. 2013 Apr 5;15(7):1622-5. doi: 10.1021/ol400399x. Epub 2013 Mar 26.

PMID:
23530743
[PubMed - indexed for MEDLINE]
16.

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.

Zoja C, Corna D, Nava V, Locatelli M, Abbate M, Gaspari F, Carrara F, Sangalli F, Remuzzi G, Benigni A.

Am J Physiol Renal Physiol. 2013 Mar 15;304(6):F808-19. doi: 10.1152/ajprenal.00376.2012. Epub 2012 Nov 7.

PMID:
23136004
[PubMed - indexed for MEDLINE]
Free Article
17.

Bardoxolone: augmenting the Yin in chronic kidney disease.

Thomas MC.

Diab Vasc Dis Res. 2011 Oct;8(4):303-4. doi: 10.1177/1479164111421034.

PMID:
21933845
[PubMed - indexed for MEDLINE]
Free Article
18.

Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).

Andress DL, Coll B, Pritchett Y, Brennan J, Molitch M, Kohan DE.

Life Sci. 2012 Oct 15;91(13-14):739-42. doi: 10.1016/j.lfs.2012.01.011. Epub 2012 Feb 2.

PMID:
22326504
[PubMed - indexed for MEDLINE]
Free Article
19.

Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD.

Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ, Warnock DG.

Am J Nephrol. 2011;33(5):469-76. doi: 10.1159/000327599. Epub 2011 Apr 21.

PMID:
21508635
[PubMed - indexed for MEDLINE]
Free Article
20.

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ.

Kidney Int. 2011 Aug;80(3):282-7. doi: 10.1038/ki.2011.79. Epub 2011 Mar 30.

PMID:
21451458
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk